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Abstract
Background: Accumulating evidence indicates aberrant DNA methylation is involved in gastric tumourigenesis, suggesting
it may be a useful clinical biomarker for the disease. The aim of this study was to consolidate and summarize published data
on the potential of methylation in gastric cancer (GC) risk prediction, prognostication and prediction of treatment response.
Methods: Relevant studies were identified from PubMed using a systematic search approach. Results were summarized by
meta-analysis. Mantel-Haenszel odds ratios were computed for each methylation event assuming the random-effects
model.
Results: A review of 589 retrieved publications identified 415 relevant articles, including 143 case-control studies on gene
methylation of 142 individual genes in GC clinical samples. A total of 77 genes were significantly differentially methylated
between tumour and normal gastric tissue from GC subjects, of which data on 62 was derived from single studies.
Methylation of 15, 4 and 7 genes in normal gastric tissue, plasma and serum respectively was significantly different in
frequency between GC and non-cancer subjects. A prognostic significance was reported for 18 genes and predictive
significance was reported for p16 methylation, although many inconsistent findings were also observed. No bias due to
assay, use of fixed tissue or CpG sites analysed was detected, however a slight bias towards publication of positive findings
was observed.
Conclusions: DNA methylation is a promising biomarker for GC risk prediction and prognostication. Further focused
validation of candidate methylation markers in independent cohorts is required to develop its clinical potential.
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Introduction
Gastric cancer (GC) remains a major clinical challenge
worldwide due to its high prevalence, poor prognosis and limited
treatment options [1]. Although the incidence of GC has declined
over the years, it continues to be the second leading cause of
cancer death and the fourth most common malignancy worldwide.
Less than 25% of GC cases are diagnosed at an early stage, and
the 5-year survival rate is only 24% in the US and Europe [2].
However, the survival rate from GC improves to over 60% if
detected at an early stage [2], emphasizing the importance of early
detection in this cancer type.
DNA methylation is an epigenetic mechanism of transcriptional
regulation, with an involvement in cancer attributed to the
inappropriate silencing of tumour suppressor genes, or loss of
oncogene repression [3]. Since the first article by Fang et al. in
1996 describing DNA hypomethylation of c-myc and c-Ha-ras in
GC [4], more than 550 studies have been published on the
involvement of aberrant DNA methylation in the development of
GC. As a result, the presence and functional consequences of
aberrant DNA methylation of more than 100 genes in GC has
been reported [5–17]. Evidence on links between aberrant DNA
methylation to H. pylori infection [1,18–22] and its involvement in
precancerous gastric epithelial lesions and GC progression
[18,19,21,23–25] are also being increasingly documented. Taken
together, these results have indicated aberrant DNA methylation
has a significant role in gastric cancer development and
progression.
The pattern of tumour DNA methylation can be useful for
cancer risk screening, prognostication and treatment prediction
[3,26–30]. Compared to somatic mutation, DNA methylation has
a higher number of aberrant alterations per cancer cell [31].
Moreover, aberrant DNA methylation occurs early in the
tumourigenesis of many cancer types [28], making it particularly
useful for risk prediction. The technical attraction of DNA
methylation is that it is chemically stable and can be detected
with a very high sensitivity of up to 1:1000 molecules [19]. Several
reports have also demonstrated that cancer-specific, methylated
DNA can be found in biological fluids, suggesting it could be a
useful marker for non-invasive diagnosis [28,32,33].
The importance of early detection to improving GC survival
outcomes and the promising evidence of DNA methylation as
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evidence of the clinical potential of DNA methylation, many
inconsistent results can be observed across studies. Hence, this
study was undertaken to consolidate information on the clinical
potential of methylation in GC by means of a meta-analysis, and
to suggest which candidate methylation events deserve further
evaluation as clinically relevant biomarkers for the disease.
Materials and Methods
Identification and eligibility of studies
A systematic literature search in PubMed for articles published
up to October 27, 2011 was performed using ‘‘‘gastric cancer’’
AND ‘‘methylation’’’ as the search terms. No restrictions were
used during the search in PubMed and the resulting studies were
manually curated according to their relevance to GC DNA
methylation. These included studies of GC in the areas of
hypermethylation and hypomethylation/demethylation of global
and target-specific regions. The title and abstract of the papers
identified in the initial search were assessed for appropriateness to
the aims of this paper. All potentially relevant articles were then
evaluated in detail and additional, relevant studies were identified
from the citations within these articles. Since the focus of this
paper was on human gene methylation, studies that analysed
methylation of H. pylori and Epstein-Barr virus (EBV) genomes in
GC progression were not considered.
Study selection and data annotation
Meta-analyses summarizing frequencies in tumour and normal
gastric tissue were restricted to data from case-control studies that
reported the frequency of methylation of individual genes in
respective groups. Data from reviews and meta-analyses of the
same studies were not considered. Information on the first author,
year of publication, gene(s) analysed, size of study population,
frequency of methylated cases and controls, methods employed for
DNA methylation analysis and the sample type were recorded for
each study (Table S1, S2). Other relevant details such as the type
of lesion, H. pylori status, Lauren classification and CpG island
methylator phenotype (CIMP) status were also recorded where
available. Clinical cases were grouped into eight categories,
namely (1) normal mucosa from non-cancer subjects, (2) matching
normal mucosa from cases with tumour, (3) chronic gastritis, (4)
intestinal metaplasia, (5) dysplastic adenoma, (6) adenocarcinoma,
(7) early GC and (8) advanced GC. Due to the small number of
studies available, clinical cases were not further classified into H.
pylori positive/negative cases or intestinal/diffuse type GC and
non-cancer subjects were not further classified into matched/
unmatched controls. For the same reason, subgroup analysis based
on the different stages of precancerous to cancerous lesions was not
performed. For consistency, a single gene name based on HUGO
nomenclature was assigned to genes with multiple designations.
Meta-analysis
Meta-analyses were performed using Review Manager 5 (The
Cochrane Collaboration, Copenhagen, Denmark). Mantel-Haens-
zel odds ratios (ORs) were computed for each gene by applying the
random-effects model. Homogeneity amongst studies for the same
gene was assessed on the basis of the x
2 test using the Cochran Q
statistic. The I
2 statistic, which measures the extent of inconsis-
tency between studies, was also assessed. The 95% confidence
interval of the odds ratio was used to evaluate differences between
groups. If the confidence intervals did not overlap, the two odds
ratios were significantly different at the 10% level (since
12(0.95*0.95)<0.9). Funnel plots as well as Begg’s tests were
used to check for publication bias [34]. Publication bias was
considered significant when the p-value was ,0.1 [35].
Results
Study characteristics
The article selection process used in this study is summarised in
Figure 1. A total of 559 studies were identified from PubMed, and
an additional 30 studies were further identified from citations of
the initial retrieved publications. Based on the appropriateness of
the title and abstract to the study objectives, 415 papers were
selected for further detailed evaluation. Of these, 190 non case-
control studies, 22 reviews, 4 commentaries and 1 meta-analysis
were excluded from case-control meta-analyses. Other case-
control studies were also excluded, as they were studies of non-
protein coding genes (e.g. methylation of micro-RNA genes), the
presentation of data was not suitable (e.g. data on individual CpG
sites, and demethylation or hypomethylation only) or frequency
data was lacking. In total, 143 case-control studies reporting the
methylation frequency of 142 individual genes were considered for
meta-analyses. The data from some studies was used in more than
one meta-analysis, as they contained data on multiple sample type
comparisons considered in this study.
Genes differentially methylated between tumour and
normal gastric tissue from gastric cancer subjects
A total of 106 case-control studies reporting on the frequency of
methylation in 122 genes in tumour and normal tissue samples
from GC subjects were identified for meta-analysis (Table S1).
Methylation of 77 of the 122 genes was significantly different
between the samples (Table 1), of which data for 62 was derived
from a single study only. Methylation was significantly higher in
tumour in 70 genes, and in normal tissue in 7 genes.
Genes differentially methylated in normal gastric tissue
from GC and non-cancer subjects
Twenty case-control studies comparing the frequency of
methylation in 34 genes between normal tissue samples from
GC and non-cancer subjects were identified for meta-analysis
(Table S2). Of these, methylation in 15 genes was significantly
different, of which the data from 11 genes were derived from a
single study only (Table 2). For all 15 genes, methylation was
higher in normal tissue from GC compared to non-cancer
subjects. Considering methylation events examined in more than
one study, 4 (p16, CDH1, DAPK, CHFR) were found to be
significantly different.
Genes differentially methylated in non-tissue samples
from GC and non-cancer subjects
A total of 26 studies reporting on methylation in 29 genes in
clinical samples other than gastric tissue, including whole blood,
plasma, serum, gastric washes, peritoneal fluid and faecal samples
from GC subjects were identified. Of these, 13 studies examining
methylation of a total of 14 genes in either serum, faecal or plasma
samples were of a case-control design and hence suitable for meta-
analysis (Table S2). Significantly different methylation frequencies
were observed in 4 genes in plasma samples, 7 genes in serum
samples and 0 in faeces (Table 2). p15 was a common gene
identified in studies of plasma and serum, making it 10 unique
genes altogether significantly different in methylation frequency in
blood samples. Methylation in only two genes (CDH1, p16) was
examined in more than one study, and both were significantly
DNA Methylation in Gastric Cancer
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subjects in meta-analysis.
Methylation as a prognostic and predictive marker for GC
A total of 28 studies were identified that investigated gene
methylation in 40 genes in relation to the survival outcome of GC
subjects (Table 3). Of the 40 genes studied, only 5 were examined
in multiple studies. Meta-analyses could not be performed on this
series of studies due to the irregular reporting of hazard ratios. A
significant association with survival was reported for methylation
in 18 of the 40 (45%) genes, although inconsistency in the finding
of significant differences was observed for all gene examined in
multiple studies.
Five studies reported on associations between the survival in GC
subjects receiving a specific chemotherapy treatment and meth-
ylation of 10 genes including TMS1, DAPK, LOX, MGMT and
CHFR [36–40]. In all 5 studies, subjects with methylation had a
worse survival than those without methylation. One study
examined survival differences between subjects treated with and
without chemotherapy according to p16 methylation status [41].
In this study, subjects without p16 methylation that received
chemotherapy had a better survival than those that did not,
whereas for subjects with p16 methylation, there was no significant
difference according to treatment status.
Effect of analytical variability and publication bias
During the annotation of studies, considerable heterogeneity
was observed in many study parameters, including the assays used,
CpG sites interrogated, stages of disease examined, and the sample
types used (e.g. fresh, frozen or paraffin-embedded tissue). Twelve
different assays were used for the evaluation of methylation, with
methylation-specific PCR (MSP) being the most common. To
examine the influence of methylation assay on study results, data
from methylation-specific PCR and quantitative methylation-
specific PCR (e.g. Methylight) analysis were compared for the gene
most frequently examined in studies comparing methylation
between gastric tumour and normal tissue (MLH1, 13 case-control
studies). There was no statistical difference (P,0.05) in the 95%
Figure 1. Flow diagram of the literature search strategy and assessment of studies identified for systematic review. Data from some
studies was used in multiple meta-analyses, as they reported on more than one case-control analysis considered.
doi:10.1371/journal.pone.0036275.g001
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the two assays (Figure S1). No significant differences according to
sample type (frozen vs. paraffin-embedded tissue), stage of disease,
or CpG sites interrogated were also observed in these studies
(results not shown).
To test for publication bias, data from the same 13 studies on
MLH1 methylation mentioned above was also examined. A trend
towards positive reporting was observed in funnel plot (Figure S2)
and Begg’s test analysis. However, these results should be
interpreted with caution as most studies were of small sample
size, and a minimum of 20 studies is usually recommended for a
reliable analysis of publication bias [42].
Discussion
Numerous studies have implicated aberrant DNA methylation
at numerous genes in different samples and models of gastric
tumourigenesis [1,5–10,12–14,16,18–22,24,43]. This implication
has in turn given rise to the notion that methylation could be a
useful biomarker for improving the clinical management of GC
[11,15,32,44,45]. To date however, this potential has not been
realized, presumably due to a lack of relevant evidence to support
the testing of methylation in the clinic.
In this study, a comprehensive review of all publications on the
frequencies and associations of methylation in gastric cancer
clinical samples was performed to consolidate information in the
field. Meta-analyses were conducted where possible to gain an
objective consensus from repeatedly investigated events. From the
analysis, lists were generated of genes significantly differentially
methylated between tumour and normal tissue sample from GC
subjects (Table 1), and normal tissue and/or blood from GC and
non-cancer subjects (Table 2), each with methylation events
annotated for their strength of association and frequency of
analysis. Findings from studies on the prognostic and predictive
significance of methylation events were also reviewed (Table 3).
These lists and additional supplementary data (Tables S1, S2)
should provide useful information from which to better assess the
clinical potential of the respective events, and prioritize further
work.
Comprising 77% (101/132) of case-control analyses (Figure 1),
the largest group of studies reviewed were those comparing the
frequency of methylation in tumour and normal gastric tissue from
GC subjects. The review identified 77 significant gene methylation
events, confirming by meta-analysis at the same time the
significantly different methylation of a number of genes commonly
implicated in tumourigenesis, including MLH1, p16, and CHFR
and RUNX3 (Table 1). These events represent useful tools for
Table 1. Genes differentially methylated in case-control studies of tumour and normal gastric tissue from GC subjects.
Gene Studies Overall OR (95% CI)
1 Gene Studies Overall OR (95% CI)
1 Gene Studies Overall OR (95% CI)
1
MLH1 15 3.16 [1.80, 5.56] CMTM3 1 4.80 [1.65, 13.98] MT1G 1 0.06 [0.01, 0.28]
p16 13 3.10 [1.22, 7.85] CST6 1 13.44 [4.72, 38.32] p15 1 11.40 [3.09, 42.03]
CHFR 10 8.66 [4.51, 16.64] CXCL12 1 14.85 [4.24, 52.03] PCDH10 1 28.67 [8.51, 96.56]
RUNX3 9 4.31 [2.14, 8.70] CYP1B1 1 34.55 [1.89, 631.93] PDX1 1 69.41 [3.89, 1239.18]
APBA1 3 3.70 [1.28, 10.66] DAB2IP 1 9.75 [2.00, 47.50] PRDM5 1 89.00 [5.29, 1496.15]
APBA2 3 8.11 [3.04, 21.63] DKK3 1 3.95 [2.36, 6.60] PTCH1a 1 163.86 [10.02, 2679.17]
HLTF 3 7.34 [2.75, 19.58] DLC1 1 83.98 [5.04, 1397.98] RAB32 1 36.89 [2.12, 641.33]
MGMT 3 5.18 [1.22, 21.98] DLEC1 1 55.08 [3.02, 1003.70] RARB 1 5.39 [1.69, 17.22]
MINT31 3 2.76 [1.04, 7.33] FLNC 1 8.10 [1.78, 36.91] RARRES1 1 0.11 [0.03, 0.41]
PRDM2 3 5.19 [2.25, 11.94] GRIK2 1 25.00 [4.81, 129.86] RASSF1A 1 11.50 [4.49, 29.44]
SFRP1 3 3.43 [1.55, 7.61] HAND1 1 30.60 [1.79, 522.23] RNF180 1 145.85 [8.70, 2446.27]
SFRP5 3 0.50 [0.27, 0.91] HIC1 1 4.75 [1.40, 16.14] SOCS1 1 5.76 [1.59, 20.92]
ITGA4 2 25.50 [6.10, 106.61] HLA-A 1 6.22 [2.45, 15.79] SPINT2 1 113.29 [6.27, 2045.31]
SFRP2 2 4.87 [1.01, 23.40] HLA-B 1 8.46 [3.01, 23.74] SYK 1 65.30 [3.85, 1108.43]
TERT 2 13.41 [1.57, 114.69] HLA-C 1 14.06 [3.82, 51.67] TAC1 1 4.71 [1.67, 13.32]
ADRA1B 1 7.20 [1.24, 41.94] HOPX 1 46.38 [18.09, 118.92] TBPL1 1 0.17 [0.05, 0.53]
APAF1 1 4.56 [1.52, 13.73] HRASLS 1 34.19 [2.01, 582.90] TCF4 1 36.00 [5.80, 223.54]
BCL2 1 29.33 [6.20, 138.78] IGF2 1 0.05 [0.01, 0.46] TFPI2 1 17.50 [3.31, 92.47]
BDNF 1 34.55 [1.89, 631.93] IQGAP2 1 22.62 [1.28, 399.63] THBD 1 4.62 [1.27, 16.84]
BNIP3 1 143.08[8.54, 2396.38] KL 1 0.18 [0.03, 0.98] THBS1 1 16.30 [3.75, 70.87]
BTG4 1 84.14 [4.61, 1534.87] KLF4 1 33.00 [1.06, 1023.56] TIMP3 1 9.00 [1.46, 55.48]
CACNA1G 1 22.15 [2.58, 189.95] LMX1A 1 12.97 [4.97, 33.83] TSPYL5 1 10.97 [3.43, 35.13]
CACNA2D3 1 7.71 [2.19, 27.12] LOX 1 5.17 [1.42, 18.79] UCHL1 1 8.75 [2.19, 34.90]
CADM1 1 36.64 [2.16, 621.68] LRP1B 1 5.20 [2.55, 10.64] XRCC1 1 12.54 [3.98, 39.53]
CDH5 1 79.22 [3.87, 1622.84] MINT12 1 3.42 [1.30, 9.00] ZIC1 1 1065.00 [49.40, 22961.75]
CDKN1C 1 0.02 [0.00, 0.20] MINT25 1 204.60 [12.28, 3409.55]
1Odds ratio (OR) describes the likelihood of gene methylation observed in tumour compared to normal gastric tissue. Only the genes for which there was a significant
difference in methylation frequency between the two groups are displayed (p,0.05). Genes for which there was no significant difference are listed in Table S1.
doi:10.1371/journal.pone.0036275.t001
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identifying new therapeutic strategies [3,28]. From the perspective
of risk markers however, these events can only be considered a first
pool of candidates to test further in more clinically relevant
analyses, as the events on their own only identify gastric tumour
samples that are already histologically diagnosable.
From studies comparing methylation levels in normal tissue,
plasma and serum from GC and non-cancer subjects, 15, 4 and 7
(Table 2) significantly different gene methylation events respec-
tively were identified. Genes with both established roles (such as
p16, CDH1, DAPK, RUNX3, p15) and lesser-known roles (such as
BX161496, SULF1, RPRM) in tumourigenesis were identified. A
number of events were in common between studies on normal
tissue and blood, such as methylation at p16, CDH1, DAPK. These
events are clinically promising, as they demonstrate discriminative
capabilities for estimating GC risk from samples that can be
obtained in current routine practice, such as during endoscopic
screening (tissue), or population or clinical screening (blood).
The hypothesis that gene silencing by methylation may also
determine severity of disease [27] has also prompted numerous
investigations of gene methylation associations with survival in
GC. In this review, 28 studies reporting on the association of
survival of GC subjects and methylation at 40 genes were also
identified. In support of the hypothesis, numerous significant
associations between methylation and poor survival were record-
ed, primarily at tumour suppressor genes (Table 3). Associations
between methylation and better survival were also reported for
four genes (PTGS2, MINT31, MLH1, MAL), presumably reflecting
that suppression of oncogenic activity by gene methylation can
also occur. However, a considerable lack of independent study and
replication of associations for most of the genes studied (Table 3)
highlights a need for further investigation in this aspect of
methylation in GC.
Data from five studies on patients receiving chemotherapy also
has suggested that DNA methylation at CHFR, DAPK, TMS1
could be useful predictors of response to chemotherapy [36–40].
However, from the design of these analyses, it is difficult to
determine whether the survival differences were due to inherent
prognostic differences or were a function of a treatment
interaction, or both. In a study of a different design, Mitsuno et
al. reported that patients with p16 methylation gained a survival
benefit from chemotherapy, while those without methylation did
not [41]. This result suggests that p16 methylation may be a useful
marker for predicting response to chemotherapy, and provides
evidence of a treatment interaction. However, this study only
examined 56 subjects in a retrospective analysis, and much further
work is required to confirm these findings.
The findings of this study highlight a promising potential for
DNA methylation in GC risk prediction, prognostication and
prediction of treatment response. However, many issues relevant
to clinical implementation remain unaddressed by the studies.
Methodologically, the studies inadequately define optimal ap-
proaches for analysis, due to their large variability in assays, PCR
primers and probes, PCR conditions, and thresholds for positivity
used. Most studies (102/143, 71%) have been based on
methylation-specific PCR, for which the non-quantitative nature
of analysis presents difficulties to quality control and standardiza-
tion. With methylation a dynamic event, protocols for sampling
are also in need of clarification, both with respect to the region or
site of sampling, and time of sampling. The distance of normal
tissue from tumour [46], and time of sampling [21,22] have all
been documented to significantly influence methylation levels.
The large variability in the genes and gene panels examined
between studies, combined with a lack of validation in indepen-
dent series and characterization of test performance characteris-
tics, also makes it difficult to define a clinically relevant test.
Variation in the interrogation of often functionally different CpG
sites [47–49] between studies of the same gene provides additional
complications. Moreover, all the gene methylation events
examined in multiple studies and significant associated with GC
(including p16, DAPK, CHFR, MLH1, RUNX3) have been
implicated as risk markers of many other cancer types
[26,27,50], raising questions about the interpretation of their
detection in asymptomatic individuals.
Of further consideration are the co-variates of analysis that
would be analyzed with methylation. Methylation has been
associated with many demographic, clinical and molecular
features, including age, gender, smoking, intestinal metaplasia,
host genetics, and H. pylori and Epstein Barr virus status [1,24]. In
addition to direct associations, many studies have also reported
Table 2. Genes differentially methylated in case-control
studies of normal tissue, serum and plasma from gastric
cancer and non-cancer subjects.
Gene Studies Overall OR (95% CI)
1
Normal gastric tissue
p16 6 2.91 [1.35, 6.30]
CDH1 3 8.54 [5.17, 14.09]
DAPK 3 6.42 [3.89, 10.60]
CHFR 2 8.55 [1.49, 49.13]
BX161496 1 9.35 [2.50, 35.04]
CDH4 1 81.67 [3.98, 1673.88]
CYP26B1 1 77.50 [8.55, 702.90]
GRIN2B 1 12.29 [1.43, 105.45]
KCNA4 1 41.08 [8.19, 205.99]
RELN 1 25.00 [1.03, 608.09]
RUNX3 1 23.10 [1.35, 396.36]
SFRP1 1 97.36 [4.93, 1922.50]
SFRP5 1 21.00 [1.13, 390.57]
TMEFF2 1 12.86 [1.52, 108.54]
WT1 1 11.43 [3.09, 42.27]
Serum
CDH1 3 15.27 [2.77, 84.28]
p16 5 12.69 [3.49, 46.10]
DAPK 1 56.72 [3.30, 974.73]
SULF1 1 5.19 [1.28, 21.08]
p15 1 75.94 [4.42, 1305.71]
SFRP2 1 71.15 [3.67, 1379.46]
SOCS1 1 25.00 [1.20, 520.73]
Plasma
MGMT 1 4.08 [1.12, 14.86]
p15 1 4.50 [1.12, 18.13]
RNF180 1 164.59 [9.37, 2891.77]
RPRM 1 191.33 [30.01, 1220.01]
1Odds ratio (OR) describes the likelihood of gene methylation observed in
samples from gastric cancer compared to non-cancer subjects. Only genes in
which there were significant differences in methylation between the two
groups are displayed (p,0.05). Genes for which there was no significant
difference are displayed in Table S2.
doi:10.1371/journal.pone.0036275.t002
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Gene Studies Author Year Cases Overall Survival
APBA1 1 An 2005 82 NS
APBA2 1 An 2005 81 NS
APC 1 Leung 2005 58 Poor OS with CDH1 (p=0.006)
BNIP3 1 Sugita 2011 80 Poor (p=0.031)
BCL6B 1 Xu 2011 309 Poor (p=0.025 (cohort I)/p=0.016 (cohort II))
CACNA2D1 1 Wanajo 2008 53 Poor (p=0.003)
CACNA2D3 1 Wanajo 2008 53 NS
CDH1 6 Graziano 2004 73 Poor (p,0.001)
Ikoma 2006 97 Poor (p,0.05)
Leung 2005 58 Poor OS with APC (p=0.006)
Napieralski 2007 61 NS
Tahara 2010 126 NS
Zazula 2006 84 NS
CST6 1 Chen 2010 52 Poor (p=0.020)
DAPK 4 Chan 2005 102 Poor
1 (p=0.0141)
Kato 2008 81 Poor OS with TMS1 (p=0.0003)
Tahara 2010 126 Poor (p=0.017)
Sugita 2011 80 NS
DKK3 1 Yu 2009 104 Poor (p,0.0001)
DMRT1 1 Jee 2009 152 NS
EBF3 1 Kim 2011 104 Poor (p=0.038)
FBP1 1 Liu 2010 46 Poor (p=0.01)
GPX1 1 Jee 2009 152 NS
GPX3 1 Jee 2009 152 NS
HOPX 1 Ooki 2010 90 Poor (p=0.029)
IGFBP6 1 Jee 2009 152 NS
IQGAP2 1 Jin 2008 36 Poor (p=0.0029)
IRF7 1 Jee 2010 152 NS
KL 1 Wang 2011 99 Poor (p=0.025)
LOX 1 Napieralski 2007 61 NS
MAGEA1/A3 1 Honda 2004 84 NS
MAL 1 Buffart 2008 179 Better (p=0.03)
MGMT 2 Napieralski 2007 61 NS
Park 2001 79 Poor (p,0.02)
MINT25 1 An 2005 82 NS
MINT31 1 An 2005 82 Better (p=0.04)
MLH1 3 An 2005 82 NS
Ishiguro 2003 102 Better (p,0.05)
Leung 2005 58 NS
p14 1 Tahara 2010 126 NS
p16 4 An 2005 82 NS
Ikoma 2006 97 NS
Napieralski 2007 61 NS
Tahara 2010 126 NS
PCDH10 1 Yu 2009 31 NS
PTGS2 1 de Maat 2007 40 Better (p=0.03)
de Maat 2007 137 Better (p=0.01)
RARB 1 Ikoma 2006 97 NS
SLC19A3 1 Liu 2009 101 NS
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methylation on GC risk [51]. Methylation events themselves also
may be linked and interact with each other [50], presenting a
challenge to define an optimal panel of methylation markers as
well. A CpG island methylator phenotype (CIMP), consisting of
distinct subtypes of GC with co-ordinated methylation patterns,
has been described [52–55], although the evidence for CIMP in
GC is not as convincing as for colorectal cancer [56,57].
In conclusion, the results of this study summarize a promising
value for DNA methylation to the risk prediction, prognostication
and prediction of response to chemotherapy of GC. However,
significant methodological and validation issues remain to be
addressed to provide the data that will enable this information to
be considered for the clinic. This includes the analysis of larger
independent sample series, application of standardized methods,
adjustment for co-variates in multivariate analysis, greater
definition of outcome endpoints and adjustment for the effect of
treatment intervention. The realization of the potential of DNA
methylation to GC clinical management awaits their resolution.
Supporting Information
Figure S1 Forest-plot of methylated studies comparing
MLH1 methylation between tumour and normal tissue
from GC subjects according to use of methylation-
specific PCR and quantitative methylation-specific PCR.
(TIF)
Figure S2 Funnel plot of all 13 studies of MLH1
methylation in tumour and normal gastric tissue from
GC subjects to evaluate publication bias. The vertical line
indicates the pooled estimate of the overall OR and the sloping
lines represent the 95% confidence interval.
(TIF)
Table S1 List of methylated genes and their component
studies for comparing differences between tumour and
normal gastric tissue from gastric cancer subjects. Meta-
analysis odd ratios (OR) and 95% confidence interval were
computed for all methylated genes analysed. Red and bold fonts
were used to indicate significant differences between groups. BS-
SSCP: bisulfite single-stranded conformation polymorphism; Bseq:
bisulfite sequencing; COBRA: combined bisulfite restriction
analysis; DPHLC: Denaturing High Performance Liquid Chro-
matography; FFPE: formalin-fixed paraffin embedded; HRM:
high resolution melting; MSP: methylation-specific polymerase
chain reaction; PCR: polymerase chain reaction; QMSP:
quantitative methylation-specific polymerase chain reaction.
(XLS)
Table S2 List of methylated genes and their component
studies for comparing differences in normal tissue,
plasma and serum between gastric cancer and non-
cancer subjects. Meta-analysis odd ratios (OR) and 95%
confidence interval were computed for all methylated genes
analysed. Red and bold fonts were used to indicate significant
differences between groups. COBRA: combined bisulfite restric-
tion analysis; MSP: methylation-specific polymerase chain reac-
tion; QMSP: quantitative methylation-specific polymerase chain
reaction.
(XLS)
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